Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inactivated quadrivalent influenza split vaccine
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The inactivated quadrivalent influenza split vaccine is a biologic vaccine developed by Sanofi Pasteur, marketed under brand names such as Fluzone Quadrivalent and VaxigripTetra. It is an inactivated, split-virion vaccine containing hemagglutinin (HA) antigens from four influenza virus strains: two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages (Victoria and Yamagata). The vaccine is produced by propagating viruses in embryonated chicken eggs, followed by inactivation with formaldehyde and chemical disruption using a non-ionic surfactant. It is indicated for active immunization against seasonal influenza A and B in individuals aged 6 months and older, providing broader protection than trivalent vaccines by including a second B-lineage strain.
- Brand names
- Fluzone QuadrivalentVaxigripTetraVaxigrip Tetra
- Other names
- QIVquadrivalent inactivated influenza vaccinesplit-virion quadrivalent influenza vaccine灭活四价流感病毒裂解疫苗
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on inactivated quadrivalent influenza split vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inactivated quadrivalent influenza split vaccine.